Not Accepting Cases

Nesina, Kazano & Oseni Side Effects

Prescription drugs Nesina, Kazano and Oseni are linked to serious side effects in patients, including pancreatitis, congestive heart failure, and pancreatic and bladder cancer. They contain alogliptin, which has been associated with joint pain, liver impairment and severe hypersensitivity reactions.

Medically Reviewed

Board-certified physicians medically review Drugwatch content to ensure its accuracy and quality.

Drugwatch partners with Physicians’ Review Network Inc. to enlist specialists. PRN is a nationally recognized leader in providing independent medical reviews.

Reviewer specialties include internal medicine, gastroenterology, oncology, orthopedic surgery and psychiatry.

Related Pages

Nesina, Kazano and Oseni are Type 2 diabetes drugs with active ingredients linked to serious side effects.

The drugs, known as dipeptidyl peptidase-4 (DPP-4) inhibitors, all contain an active ingredient called alogliptin. Kazano also contains metformin. Oseni contains pioglitazone.

DPP-4 inhibitors, along with all three of the active ingredients found in either Nesina, Kazano or Oseni, are linked to several serious side effects and health complications, including pancreatitis, heart failure and edema (swelling associated with fluid buildup in the body), pancreatic cancer and bladder tumors.

Other serious side effects associated with these three diabetes medications include:
  • Joint pain (Nesina, Kazano and Oseni)
  • Fractures (Oseni)
  • Lactic acidosis (Kazano)
  • Liver impairment (Nesina, Kazano and Oseni)
  • Severe hypersensitivity (allergic) reactions, including a severe, potentially deadly skin disease called Stevens-Johnson syndrome (Nesina, Kazano and Oseni)

Pancreatitis

After taking Nesina, Kazano or Oseni, people reported cases of acute pancreatitis, a condition where the pancreas becomes inflamed and swollen. In severe cases, this can lead to hospitalization and even death.

Researchers at Johns Hopkins University reported that people who took DPP-4s were twice as likely to suffer from pancreatitis that required hospitalization.

Signs and Symptoms:
  • Abdominal pain, primarily felt in the upper left side or middle of the abdomen
  • Looking ill
  • Fever
  • Nausea and/or vomiting
  • Sweating
  • Clay-colored stools
  • Feeling full and/or gaseous
  • Hiccups
  • Indigestion
  • Yellowing of the skin and whites of the eyes (jaundice)
  • Swollen abdomen

Abdominal pain associated with acute pancreatitis comes on suddenly and persists for several days. The pain becomes more constant and severe as the condition progresses.

Treatment and Complications of Pancreatitis

Treatment for acute pancreatitis is carried out in a hospital, usually over a period of a few days up to a week or more. Health care providers may administer pain medicines along with intravenous (IV) fluids. Food or fluid ingested by mouth may be stopped to limit the activity of the pancreas.

Other complications associated with the disease include:
  • Acute kidney failure
  • Acute respiratory distress syndrome (ARDS)
  • Buildup of fluid in the abdomen (ascites)
  • Cysts or abscesses in the pancreas
  • Heart Failure
  • Low blood pressure

Sometimes, in severe cases where vomiting and pain does not improve, a tube is inserted through the nose or mouth to remove the contents in the stomach. This procedure is called nasogastric suctioning. In the most severe cases, surgery may be needed to remove damaged, dead or infected pancreatic tissue.

Death rates are higher when the following factors are present: Hemorrhagic pancreatitis (bleeding), liver, heart or kidney impairment or necrotizing pancreatitis (when the pancreatic tissue dies).

Pancreatitis can sometimes return. Repeat episodes of acute pancreatitis can lead to chronic (long-term) pancreatitis. This type of pancreatitis does not heal or improve. Instead, it persists and worsens over time, leading to permanent damage to the organ.

Pancreatic Cancer

Controversy still exists over whether DPP-4s can cause pancreatic cancer, and both the FDA and European Medicines Agency say that not enough evidence exists to support this link.

In one study by Alexandra Butler and colleagues published in Diabetes, the researchers examined the pancreases of organ donors who were using DPP-4s and other incretin-based therapies. Researchers found abnormal cells “with the potential for evolution into neuroendocrine tumors.”

Fact
Pancreatic cancer symptoms are sometimes not detected until after the disease has spread.

Outlook for Pancreatic Cancer Patients

Pancreatic cancer is difficult to detect early. Most patients have no symptoms until after the cancer has already spread. By the time the cancer has spread, a patient’s five-year survival rate drops to about one to 41 percent, depending on the location and type of cancer affecting the pancreas.

Patients with tumors that can be treated with surgery have much higher survival rates than those not treated or unable to be treated (or removed) by surgery. Treatment options depend on the stage of tumor and whether it has spread to nearby tissues, organs or lymph nodes.

Chemotherapy and Radiation Therapy

Aside from surgery, other treatment options include chemotherapy and radiation therapy. These treatments may be used together in some cases, and may lead to the cancer being cured in a small number of people.

When the cancer is advanced, the primary goal of treatment is to manage the patient’s pain and other symptoms.

Heart Failure

A 2013 study in the New England Journal of Medicine by researchers at Brigham and Women’s Hospital in Boston showed that Nesina did not increase heart attack risk. However, doctors also determined that DPP-4s may increase the risk of heart failure.

In the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial, researchers found more patients suffered congestive heart failure with Nesina than those taking a placebo. The medication insert suggests health care providers consider the risk and benefits of prescribing Nesina to patients with a history of kidney or heart failure.

In 2016, the FDA required drug makers to add a warning for heart failure to all alogliptin-containing medications.

What Is Heart Failure?

Most heart-failure cases involve both chambers of the organ

Heart failure occurs when the heart is unable to pump enough blood to meet the body’s needs. In some cases of heart failure, the heart cannot fill with enough blood, and in other cases, the heart cannot pump blood throughout the body with enough force. Some patients may experience both problems.

The serious heart condition can affect the right side of the heart only, or it can affect both sides of the heart. Most cases involve both sides. Right-side heart failure can result in fluid buildup in the feet, ankles, legs, liver, abdomen and even the veins in the neck. When heart failure affects both the right and left side of the heart, symptoms might include shortness of breath and fatigue, or extreme tiredness.

Congestive Heart Failure

Thiazolidinediones, including pioglitazone, an active ingredient in Oseni, have been determined to cause or worsen congestive heart failure in some patients. This occurrence is especially apparent at the initiation of drug treatment and following dose increases.

Congestive heart failure, also just called heart failure, causes blood and other bodily fluids to back up in the body, primarily affecting the liver, lungs, hands and feet.

Signs and symptoms include:
  • Excessive, rapid weight gain
  • Shortness of breath (dyspnea), even occurring at rest
  • Chest pain (angina)
  • Edema (swelling caused by fluid in the body’s tissues)

Urinary Bladder Tumors

A two-year laboratory study of the carcinogenicity (potential to cause cancer) of Oseni showed tumors in the urinary bladders of male rats. Additionally, during a three-year randomized clinical trial called PROactive, 14 patients out of a total of 2,605 participants taking pioglitazone and 5 patients out of 2,633 participants taking a placebo (dummy pill), were diagnosed with bladder cancer. This shows an almost three-times greater risk of bladder cancer in patients taking drugs containing pioglitazone, such as Oseni, compared with those who have not taken the drug.

Findings regarding the risk of bladder cancer in patients exposed to pioglitazone varied in subsequent observational studies, with some finding an increased risk of bladder cancer associated with the active ingredient in Oseni, and others finding no statistically significant increase.

Signs and symptoms of bladder cancer include:
  • Blood in the urine
  • Lower back pain, often on one side
  • Loss of appetite and weight loss
  • Feeling tired or weak
  • Swelling in the feet
  • Bone pain (when the cancer has spread)
Symptoms also include changes in urination, such as:
  • Having to urinate more often than usual
  • Pain or burning during urination
  • Urgency to urinate, even when the bladder is not full
  • Having trouble urinating or having a weak urine stream
  • Inability to urinate

Outlook for Bladder Cancer Patients

Bladder cancer can often be detected early because blood in the urine called hematuria is often the first symptom, and it’s usually accompanied by other bothersome urinary symptoms as well.

When bladder cancer is found early on, the survival rate is relatively high, with stage I cancer having a five-year survival rate of nearly 90 percent. Once the cancer has spread to other parts of the body, however, it becomes much more difficult to treat with a patient’s, five-year survival rate dropping drastically to about 15 percent, according to the American Cancer Society (ACS).

Treatments for bladder cancer can include surgery, radiation therapy, chemotherapy and biologic therapy, which boosts the body’s own ability to fight off the cancer.

A patient’s overall outlook depends on certain factors that can affect their chance of recovery as well as treatment options available to them.

Risk Factors might include:
  • The stage of the cancer
  • The type of bladder cancer cells
  • Whether there are groups of abnormal cells in other parts of the bladder with the potential to become cancer and spread to nearby tissue
  • The patient’s age and overall health
  • How many tumors are present
  • The size of the tumors
  • Whether the tumor or tumors are recurrent, coming back after treatment

Other Side Effects

Nesina, Kazano and Oseni are associated with several other serious side effects and complications, some of which can lead to permanent injury or be fatal. Some of these adverse effects are linked to the class of drugs to which the diabetes medications belong to (DPP-4 drugs), or their active ingredients, including metformin (Kazano), alogliptin (Nesina, Kazano and Oseni) and pioglitazone (Oseni).

Joint Pain

In 2016, the FDA warned that DPP-4 drugs, including Nesina, Kazano and Oseni, may cause severe and persistent joint pain. Patients who took the drugs for as little as one day suffered joint pain. Fortunately, most patients who stopped taking the drugs had relief of symptoms in less than a month.

Fractures

Bone fractures have been linked to patients’ use of pioglitazone

Incidences of bone fracture have been linked to patients’ use of pioglitazone during the clinical trial PROactive (the Prospective Pioglitazone Clinical Trial in Macrovascular Events), according to drug labeling for Oseni.

In the randomized study, female patients taking pioglitazone experienced 5.1 percent of bone fractures, while female participants given a placebo (dummy pill) experienced only a 2.5 percent incidence of the same. These occurrences of bone fractures were noted after the first year of treatment and persisted throughout the course of the study.

No similar increase in bone fractures was observed in men treated with Oseni.

Lactic Acidosis

There have been cases of metformin-associated lactic acidosis, some of which have resulted in death. Cases of this metabolic imbalance in patients taking Kazano have come on subtly with nonspecific symptoms, such as a general feeling of sickness, muscle and abdominal pain, respiratory problems, and an increased desire for sleep.

However, some more severe cases have resulted in abnormally low body temperature, low blood pressure and certain arrhythmias (irregular heart rate) called resistant bradyarrhythmias.

Patients diagnosed with this condition require prompt hemodialysis, or the process of purifying blood in people with nonfunctional or impaired kidneys.

The risk of occurrence of metformin-associated lactic acidosis is increased in certain individuals including those who:
  • Have kidney impairment
  • Are using certain other medications along with metformin
  • Are aged 65 or older
  • Undergo radiological studies (such as X-rays) with contrast
  • Suffer from acute congestive heart failure, especially with hypoxemia (abnormally low level of oxygen in the blood)
  • Consume excessive alcohol
  • Have liver impairment

Liver Impairment

Fatal and nonfatal cases of liver failure have been reported in patients taking alogliptin. Some of these reports contain insufficient information to establish probable cause.

Some patients may present with elevated liver enzymes or abnormal liver tests that persist or worsen, necessitating discontinuation of the drug (Nesina, Kazano or Oseni).

Symptoms that may be indicative of injury or damage to the liver include fatigue, anorexia (self-starvation and excessive weight loss), right upper abdominal discomfort or pain, dark urine, or yellowing of the skin and whites of the eyes (jaundice).

Severe Hypersensitivity Reactions

Postmarketing reports have shown serious hypersensitivity (allergic) reactions in patients taking medications containing alogliptin, present in Nesina, Kazano and Oseni.

These reactions can include:
  • Anaphylaxis, which is a life-threatening, whole-body allergic reaction
  • Angioedema, or swelling of the lower layer of skin and tissue just under the skin (mucous membranes)
  • Severe skin reactions, including Stevens-Johnson syndrome (a potentially deadly skin disease resulting from drug reactions)

Please seek the advice of a medical professional before making health care decisions.

Related Pages

Did you find Drugwatch helpful?

12 Cited Research Articles

  1. American Cancer Society. (2016, May 23). Signs and Symptoms of Bladder Cancer. Retrieved from https://www.cancer.org/cancer/bladder-cancer/detection-diagnosis-staging/signs-and-symptoms.html
  2. American Cancer Society. (2016, May 23). Survival Rates for Bladder Cancer. Retrieved from https://www.cancer.org/cancer/bladder-cancer/detection-diagnosis-staging/survival-rates.html
  3. American Cancer Society. (2016, May 31). Pancreatic Cancer Survival Rates, by Stage. Retrieved from https://www.cancer.org/cancer/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html
  4. American Heart Association. (2017, May 8). Classes of Heart Failure. Retrieved from https://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-Failure_UCM_306328_Article.jsp
  5. DailyMed. NIH. (2016, December 15). Label: Oseni – alogliptin and pioglitazone tablet, film coated. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55
  6. DailyMed. NIH. (2017, February 22). Label: Kazano – alogliptin and metformin hydrochloride tablet, film coated. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83cb7914-a683-47bb-a713-f2bc6a596bd2
  7. DailyMed. NIH. (2016, December 15). Label: Nesina – alogliptin tablet, film coated. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3768c7e-aa4c-44d3-bc53-43bb7346c0b0
  8. MedlinePlus. NIH. (2014, February 11). Acute pancreatitis. Retrieved from http://salud.wikiplus.org/medlineplus/ency/article/000287.htm
  9. MedlinePlus. NIH. (2015, August 1). Pancreatic cancer. Retrieved from https://medlineplus.gov/ency/article/000236.htm
  10. MedlinePlus. NIH. (2016, June 7). Bladder Cancer. Retrieved from https://medlineplus.gov/bladdercancer.html
  11. National Cancer Institute. NIH. (2017, April 27). Bladder Cancer Treatment (PDQ) – Patient Version. Retrieved from https://www.cancer.gov/types/bladder/patient/bladder-treatment-pdq
  12. National Heart, Lung and Blood Institute. NIH. What Is Heart Failure? Retrieved from https://www.nhlbi.nih.gov/health/health-topics/topics/hf/
View All Sources
Who Am I Calling?

Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.

Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.

(888) 645-1617

To contact Drugwatch Managing Editor Kevin Connolly, call (855) 839-9780.